Novartis has reached an agreement to take control of Kate Therapeutics, a developer of gene therapies for inherited neuromuscular diseases, including Duchenne muscular dystrophy (DMD). The transaction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback